Table 2 Comparison of resveratrol intervention among included studies
First author (Year) | Identical with placebo | Dosage and frequency | Total dosage/daily | Route of administration | Administration form | Alone or in combination with other medications | Company | Purity | Adverse events |
|---|---|---|---|---|---|---|---|---|---|
Wong et al. (2020) | Yes | 75 mg twice daily (morning and evening) | 150 mg | Oral | Capsule | Alone | Evolva SA (Reinach, Switzerland) | > 98% tans-resveratrol | Not related to resveratrol supplementation |
Ornstrup et al. (2014) | Unclear | 500 mg twice daily and 75 mg twice daily | 1000 mg and 150 mg | Oral | Tablet | Alone | Resv: Evolva SA (Reinach, Switzerland) Placebo: Robinson Pharma (Santa Ana, CA, USA) | > 98% tans-resveratrol | One case of transient pruritic skin rash |
Bo et al. (2018) | Year | 500 mg/daily and 40 mg/daily (morning) | 500 mg and 40 mg | Oral | Capsule | Hypoglycemic treatment | Biotivia Bioceuticals (International SrL, Italy) | 99.7% and a 97.9% purity of trans-resveratrol | No serious adverse event |
Poulsen et al. (2014) | Unclear | 500 mg three times daily (morning) | 1500 mg | Oral | Tablet | Alone | Resv: Fluxome (Stenlose, Denmark) Placebo: Robinson Pharma (Santa Ana, CA, USA) | Unclear | The rate is not significantly different from placebo |
Heebøll et al. (2016) | Yes | 500 mg three times daily | 1500 mg | Oral | Capsule | Alone | Unclear | Unclear | Two serious cases: gastrointestinal side effects and febrile leukopenia and thrombocytopenia |
Anton et al. (2014) | Unclear | 150 mg twice daily and 500 mg twice daily (morning and evening) | 1000 mg and 300 mg | Oral | Capsule | Alone | Reserveage Organics | within 7% of the stated mg dose | The rate is not significantly different from placebo |
Movahed et al. (2013) | Unclear | 500 mg twice daily | 1000 mg | Oral | Capsule | Antidiabetic medications | Resv: Biotivia, Bioceuticals International SrI, (Italy) Placebo: Biotivia, Bioceuticals International SrI, (Italy) | 99% | No serious adverse event |
Asghari et al. (2018) | Yes | 300 mg twice daily | 600 mg | Oral | Capsule | Alone | Unclear | Unclear | No serious adverse event |
Tomé-Carneiro et al. (2013) | Yes | 8 mg for the first 6 months and 16 mg for the following 6 months | 8 mg for the first 6 months 16 mg for the following 6 months | Oral | Capsule | Statins, β-blockers, antiplatelets, RAS-blockers treatment and oral antidiabetics | Laboratorios Actafarma S.L. (Pozuelo de Alarcón, Spain) | Unclear | No adverse event |
van der Made et al. (2015) | Yes | 75 mg twice daily | 150 mg | Oral | Capsule | Antidepressants, antihypertensives or antacids | DSM Nutritional Products Ltd. (Kaiseraugst, Switzerland) | 99.9% trans-resveratrol | No adverse event |